13G Filing: Kerrisdale Capital and Adamas Pharmaceuticals Inc (ADMS)

---

Item 1(a) Name of Issuer.

Adamas Pharmaceuticals, Inc. (the Issuer)

Item 1(b) Address of Issuers Principal Executive Offices.

1900 Powell Street, Suite 750

Emeryville, CA 94608

ITEM 2(a). NAME OF PERSON FILING:

The Reporting
Persons are:

(i) Kerrisdale Partners Master Fund Ltd (the Master Fund), a Cayman Islands exempted company;

(ii) Kerrisdale Advisers, LLC (the Adviser), a New York limited liability company and the investment manager to the Master Fund, with respect to
the Common Stock held by the Master Fund;

(iii) Sahm Adrangi, a Canadian citizen and the managing member of the Adviser, with respect to the Common Stock
held by the Master Fund.

ITEM 2(b). Address of Principal Business Office, or, if non, Residence:

The address for the Master Fund is:

c/o Intertrust Corporate
Services (Cayman) Limited

190 Elgin Avenue

George Town,
Grand Cayman KY1-9005 Cayman Islands

The address for each of the Adviser and Mr. Adrangi is:

1212 Avenue of the Americas, 3rd Floor

New York, NY 10036

Item 2(c) Citizenship:

Master Fund – Cayman Islands

Adviser – New York

Sahm Adrangi – Canada

Item 2(d) Title of Class of Securities.

Common
Stock, par value $0.001 per share (Common Stock)

Item 2(e) CUSIP Number.

00548A106

Item 3 If this statement is Filed pursuant to
Rules 13d-1(b) or 13d-2(b) or (c), check whether the Filing person is.

Not Applicable